

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI764866

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the U.S. Provisional Application Number 63/333,496 to U.S. Provisional Application Number 63/331,496 previously recorded on Reel 69785 Frame 962. Assignor(s) hereby confirms the Assignment.

## CONVEYING PARTY DATA

Name	Execution Date
inQB8 Medical Technologies, LLC	12/26/2024

## RECEIVING PARTY DATA

<b>Company Name:</b>	Relief Cardiovascular, Inc.
<b>Street Address:</b>	3188 Airway Avenue
<b>Internal Address:</b>	Suite K1
<b>City:</b>	Costa Mesa
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92626

## PROPERTY NUMBERS Total: 19

Property Type	Number
Application Number:	63484635
Application Number:	63336924
Application Number:	18635983
Application Number:	63331496
Application Number:	18300293
Application Number:	63512152
Application Number:	63591304
Application Number:	63582723
Application Number:	63582726
Application Number:	63667040
Application Number:	63591345
Patent Number:	11883030
Patent Number:	11974751
PCT Number:	US2320471
PCT Number:	US2318555
PCT Number:	US2436769
PCT Number:	US2451659

PATENT

Property Type	Number
PCT Number:	US2446253
PCT Number:	US2446716

#### CORRESPONDENCE DATA

**Fax Number:** 9497609502

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 9497600404

**Email:** efiling@knobbe.com,emilie.albert@knobbe.com

**Correspondent Name:** Docketing Department

**Address Line 1:** 2040 Main Street

**Address Line 2:** 14th Floor

**Address Line 4:** Irvine, CALIFORNIA 92614

<b>ATTORNEY DOCKET NUMBER:</b>	RLF.008PR
--------------------------------	-----------

<b>NAME OF SUBMITTER:</b>	Ms. Emilie Albert
---------------------------	-------------------

<b>SIGNATURE:</b>	/Ms. Emilie Albert/
-------------------	---------------------

<b>DATE SIGNED:</b>	01/17/2025
---------------------	------------

#### Total Attachments: 12

source=ORG\_ASSIGN\_Redacted#page1.tiff  
source=ORG\_ASSIGN\_Redacted#page2.tiff  
source=ORG\_ASSIGN\_Redacted#page3.tiff  
source=ORG\_ASSIGN\_Redacted#page4.tiff  
source=ORG\_ASSIGN\_Redacted#page5.tiff  
source=ORG\_ASSIGN\_Redacted#page6.tiff  
source=ORG\_ASSIGN\_Redacted#page7.tiff  
source=ORG\_ASSIGN\_Redacted#page8.tiff  
source=ORG\_ASSIGN\_Redacted#page9.tiff  
source=ORG\_ASSIGN\_Redacted#page10.tiff  
source=ORG\_ASSIGN\_Redacted#page11.tiff  
source=ORG\_ASSIGN\_Redacted#page12.tiff

**PATENT ASSIGNMENT**

WHEREAS, **inQB8 Medical Technologies, LLC**, (hereinafter "ASSIGNOR") a limited liability company organized and existing under the laws of the State of Delaware, and having a place of business at 123 Church Street, Winchester, MA 01890, is the owner by assignment of patent(s), patent application(s) and the invention(s) listed on Schedule A, including the rights in and to any provisionals, continuations, divisionals, reissues or re-examinations, and the corresponding foreign patent applications and foreign patents arising out of the aforementioned patent(s) and patent application(s), and any future patents issuing therefrom, and the inventions claimed in said patent(s) and patent application(s) (referred to collectively hereinafter as the "PATENT RIGHTS"), and

WHEREAS **Relief Cardiovascular, Inc.** (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a place of business at 3188 Airway Avenue, Suite K1, Costa Mesa, CA 92626, desires to acquire the entire right, title and interest in the PATENT RIGHTS, in accordance with agreements entered into with ASSIGNOR;

WHEREAS, ASSIGNOR and ASSIGNEE have entered into a certain Amended and Restated Assignment and License Agreement, dated as of December 26, 2024, pursuant to which ASSIGNOR agreed to assign to ASSIGNEE all of ASSIGNOR's right, title, and interest in and to the PATENT RIGHTS;

NOW, THEREFORE, to all whom it may concern be it known that, for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, ASSIGNOR has sold, assigned, and transferred and by these presents does hereby sell, assign and transfer unto ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR'S entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the inventions claimed in said PATENT RIGHTS, including any right of priority thereto, together with ASSIGNOR's entire right, title and interest in and to the patent(s) and patent application(s) listed on Schedule A and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions, to said patent(s) and patent application(s), and any right, title and interest ASSIGNOR may have in provisional applications to which said PATENT RIGHTS claim priority; said invention(s), application(s) and patent(s) to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment;

AND, ASSIGNOR hereby acknowledges that this assignment, being of its entire right, title and interest in and to said invention(s), application(s) and patent(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all patents to ASSIGNEE in its own name as assignee of ASSIGNOR's entire right, title and interest therein;

AND, ASSIGNOR hereby further agrees for itself and its successors, assigns, agents, and legal representatives to, to the extent reasonably requested to do so and at ASSIGNEE's reasonable expense, (i) provide statements or testimony in any interference or proceeding in which said patent(s) or patent application(s) or invention(s) directed thereto may be involved; (ii) to communicate to ASSIGNEE, its successors, assigns and legal representatives, any facts known to ASSIGNOR regarding said invention(s), and (iii) to testify in any legal proceedings, sign all lawful papers, make all rightful oaths, and generally execute upon reasonable request and at ASSIGNEE's reasonable expense any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid inventions to ASSIGNEE, its successors, assignees, and legal representatives, including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications, and (iv) generally do everything reasonably possible to aid ASSIGNEE, its successors, assigns and legal representatives, to obtain, record and enforce full protection for said invention(s) in all countries, but in each instance at ASSIGNEE's reasonable expense;

AND, ASSIGNOR does hereby authorize and request the Director of the United States Patent and Trademark Office and any officials of any country or countries other than the United States, whose duty is to issue patents or other forms of industrial property protection, to issue the same as shall be granted upon any application included in said PATENT RIGHTS to ASSIGNEE, its successors, assigns, or legal representatives;

AND, ASSIGNOR covenants and agrees that it has full right to convey the entire right, title, and interest assigned, and it has not executed and will not execute any agreement in conflict herewith;

**IN TESTIMONY WHEREOF**, ASSIGNOR and ASSIGNEE by their duly authorized representative acting on their own free will have caused this instrument to be duly executed and have hereunto set his hand and affixed our seal on the dates set forth below.

The undersigned (whose title is supplied below) is authorized to act on behalf of **inQB8 Medical Technologies, LLC**.

Signature: J. Brent Ratz Date: December 26, 2024

Name (printed): J Brent Ratz

Title (printed): CEO, President

The undersigned (whose title is supplied below) is authorized to act on behalf of **Relief Cardiovascular, Inc.**

Signature: Alex Cooper Date: December 26, 2024

Name (printed): Alex Cooper

Title (printed): Chief Executive officer

# SCHEDULE A

<u>Appl'n or Patent No.</u>	<u>Filing or Issue Date</u>	<u>Country</u>	<u>Att'y Docket No.</u>
63/336,924	04/29/2022	USA	INQB.014PR
63/484,635	02/13/2023	USA	INQB.014PR2
11,883,030	01/30/2024	USA	INQB.014A
11,974,751	05/07/2024	USA	INQB.014D1
18/635,983	04/15/2024	USA	INQB.014C1
PCT/US2023/020471	04/28/2023	PCT	INQB.014WO
<del>63/333,496</del>	4/15/2022	USA	INQB.017PR
18/300,293	4/13/2023	USA	INQB.017A
PCT/US2023/018555	4/13/2023	PCT	INQB.017WO
63/512,152	07/06/2023	USA	INQB.023PR
63/591,304	10/18/2023	USA	INQB.023PR2
63/591,345	10/18/2023	USA	INQB.027PR
63/582,723	09/14/2023	USA	INQB.028PR
63/582726	09/14/2023	USA	INQB.029PR

63/331,496  
*AC*  
 1/16/25  
 1/16/25

**PATENT ASSIGNMENT COVER SHEET**

Assignment ID: 740125

Electronic Version v1.1  
Stylesheet Version v1.2

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
inQB8 Medical Techn ologies, LLC	12/26/2024
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Relief Cardiovascul ar, Inc.
<b>Street Address:</b>	3188 Airway Avenue
<b>Internal Address:</b>	Suite K1
<b>City:</b>	Costa Mesa
<b>State/Country:</b>	CALIFORNIA UNITED STATES
<b>Postal Code:</b>	92626
<b>PROPERTY NUMBERS Total:19</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	63484635
<b>Application Number:</b>	63336924
<b>Patent Number:</b>	11883030
<b>Patent Number:</b>	11974751
<b>Application Number:</b>	18635983
<b>PCT Number:</b>	US2320471
<b>Application Number:</b>	63333496
<b>Application Number:</b>	18300293
<b>PCT Number:</b>	US2318555
<b>Application Number:</b>	63512152
<b>Application Number:</b>	63591304
<b>Application Number:</b>	63591345
<b>Application Number:</b>	63582723
<b>Application Number:</b>	63582726
<b>Application Number:</b>	63667040

**PATENT**  
**REEL: 069939 FRAME: 0008**



<b>PCT Number:</b>	US2436769
<b>PCT Number:</b>	US2451659
<b>PCT Number:</b>	US2446253
<b>PCT Number:</b>	US2446716

**CORRESPONDENCE DATA**

**Fax Number:** 9497609502

**Phone:** 9497600404

**Email:** efilings@knobbe.com,emilie.albert@knobbe.com

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Correspondent Name:** Docketing Department

**Address Line 1:** 2040 Main Street

**Address Line 2:** 14th Floor

**Address Line 4:** Irvine , CALIFORNIA 92614

**ATTORNEY DOCKET  
NUMBER:**

RLF.007-012\*

**NAME OF SUBMITTER:**

Ms. Emilie Albert

**Signature:**

Ms. Emilie Albert

**Date:**

01/08/2025

**TOTAL ATTACHMENTS: 1**

source= [SIGNED] Assignment - INQB to RLF.pdf

**PATENT ASSIGNMENT**

WHEREAS, **inQB8 Medical Technologies, LLC**, (hereinafter "ASSIGNOR") a limited liability company organized and existing under the laws of the State of Delaware, and having a place of business at 123 Church Street, Winchester, MA 01890, is the owner by assignment of patent(s), patent application(s) and the invention(s) listed on Schedule A, including the rights in and to any provisionals, continuations, divisionals, reissues or re-examinations, and the corresponding foreign patent applications and foreign patents arising out of the aforementioned patent(s) and patent application(s), and any future patents issuing therefrom, and the inventions claimed in said patent(s) and patent application(s) (referred to collectively hereinafter as the "PATENT RIGHTS"), and

WHEREAS **Relief Cardiovascular, Inc.** (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a place of business at 3188 Airway Avenue, Suite K1, Costa Mesa, CA 92626, desires to acquire the entire right, title and interest in the PATENT RIGHTS, in accordance with agreements entered into with ASSIGNOR;

WHEREAS, ASSIGNOR and ASSIGNEE have entered into a certain Amended and Restated Assignment and License Agreement, dated as of December 26, 2024, pursuant to which ASSIGNOR agreed to assign to ASSIGNEE all of ASSIGNOR's right, title, and interest in and to the PATENT RIGHTS;

NOW, THEREFORE, to all whom it may concern be it known that, for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, ASSIGNOR has sold, assigned, and transferred and by these presents does hereby sell, assign and transfer unto ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR'S entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the inventions claimed in said PATENT RIGHTS, including any right of priority thereto, together with ASSIGNOR's entire right, title and interest in and to the patent(s) and patent application(s) listed on Schedule A and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions, to said patent(s) and patent application(s), and any right, title and interest ASSIGNOR may have in provisional applications to which said PATENT RIGHTS claim priority; said invention(s), application(s) and patent(s) to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment;

AND, ASSIGNOR hereby acknowledges that this assignment, being of its entire right, title and interest in and to said invention(s), application(s) and patent(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all patents to ASSIGNEE in its own name as assignee of ASSIGNOR's entire right, title and interest therein;

AND, ASSIGNOR hereby further agrees for itself and its successors, assigns, agents, and legal representatives to, to the extent reasonably requested to do so and at ASSIGNEE's reasonable expense, (i) provide statements or testimony in any interference or proceeding in which said patent(s) or patent application(s) or invention(s) directed thereto may be involved; (ii) to communicate to ASSIGNEE, its successors, assigns and legal representatives, any facts known to ASSIGNOR regarding said invention(s), and (iii) to testify in any legal proceedings, sign all lawful papers, make all rightful oaths, and generally execute upon reasonable request and at ASSIGNEE's reasonable expense any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid inventions to ASSIGNEE, its successors, assignees, and legal representatives, including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications, and (iv) generally do everything reasonably possible to aid ASSIGNEE, its successors, assigns and legal representatives, to obtain, record and enforce full protection for said invention(s) in all countries, but in each instance at ASSIGNEE's reasonable expense;

AND, ASSIGNOR does hereby authorize and request the Director of the United States Patent and Trademark Office and any officials of any country or countries other than the United States, whose duty is to issue patents or other forms of industrial property protection, to issue the same as shall be granted upon any application included in said PATENT RIGHTS to ASSIGNEE, its successors, assigns, or legal representatives;

AND, ASSIGNOR covenants and agrees that it has full right to convey the entire right, title, and interest assigned, and it has not executed and will not execute any agreement in conflict herewith;

**IN TESTIMONY WHEREOF**, ASSIGNOR and ASSIGNEE by their duly authorized representative acting on their own free will have caused this instrument to be duly executed and have hereunto set his hand and affixed our seal on the dates set forth below.

The undersigned (whose title is supplied below) is authorized to act on behalf of **inQB8 Medical Technologies, LLC**.

Signature: J. Brent Ratz Date: December 26, 2024

Name (printed): J Brent Ratz

Title (printed): CEO, President

The undersigned (whose title is supplied below) is authorized to act on behalf of **Relief Cardiovascular, Inc.**

Signature: Alex Cooper Date: December 26, 2024

Name (printed): Alex cooper

Title (printed): Chief Executive officer

**SCHEDULE A**

<b><u>Appl'n or Patent No.</u></b>	<b><u>Filing or Issue Date</u></b>	<b><u>Country</u></b>	<b><u>Att'y Docket No.</u></b>
63/336,924	04/29/2022	USA	INQB.014PR
63/484,635	02/13/2023	USA	INQB.014PR2
11,883,030	01/30/2024	USA	INQB.014A
11,974,751	05/07/2024	USA	INQB.014D1
18/635,983	04/15/2024	USA	INQB.014C1
PCT/US2023/020471	04/28/2023	PCT	INQB.014WO
63/333,496	4/15/2022	USA	INQB.017PR
18/300,293	4/13/2023	USA	INQB.017A
PCT/US2023/018555	4/13/2023	PCT	INQB.017WO
63/512,152	07/06/2023	USA	INQB.023PR
63/591,304	10/18/2023	USA	INQB.023PR2
63/591,345	10/18/2023	USA	INQB.027PR
63/582,723	09/14/2023	USA	INQB.028PR
63/582726	09/14/2023	USA	INQB.029PR